Holen Sie sich die Stockscreener-App
11.40
3.05%
0.40
Handel nachbörslich:
11.39
-0.010
-0.09%
Schlusskurs vom Vortag:
$11.00
Offen:
$11.19
24-Stunden-Volumen:
627.67K
Relative Volume:
0.90
Marktkapitalisierung:
$653.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-59.85M
KGV:
-12.87
EPS:
-0.8857
Netto-Cashflow:
$-54.54M
1W Leistung:
+17.46%
1M Leistung:
+24.02%
6M Leistung:
+516.03%
1J Leistung:
+860.59%
1-Tages-Spanne:
$11.13
$11.57
1-Wochen-Bereich:
$9.71
$11.57
52-Wochen-Spanne:
$1.16
$12.48
Climb Bio Inc Stock (CLYM) Company Profile
Firmenname
Climb Bio Inc
Sektor
Branche
Telefon
1-866-857-2596
Adresse
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
11.42 | 629.87M | 0 | -59.85M | -54.54M | -0.8857 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Mizuho | Outperform |
| 2026-03-24 | Eingeleitet | B. Riley Securities | Buy |
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2026-03-11 | Eingeleitet | Raymond James | Strong Buy |
| 2026-03-05 | Eingeleitet | Wedbush | Outperform |
| 2026-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | William Blair | Outperform |
| 2025-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-08-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-06-06 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Climb Bio Inc Aktie (CLYM) Neueste Nachrichten
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026 - markets.businessinsider.com
Climb Bio to share antibody trial data at European renal congress - Stock Titan
Climb Bio Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentOpen Trading Community - Newser
Climb Bio teases key Budoprutug, CLYM116 readouts at BioConnect - MSN
Climb Bio Inc. (CLYM) Surges Over 3% – Approaching Key Resistance ZoneTrending Momentum Stocks - newser.com
Climb Bio, Inc. drives new focus on APRIL-targeted B cell therapies at Dallas workshop - Traders Union
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect - sharewise.com
Climb Bio, Inc.Common Stock (CLYM) Stock Price, News, Quote & History - FinancialContent
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Climb Bio (CLYM) and Boston Scientific (BSX) - The Globe and Mail
Climb Bio (CLYM) Stock Price, News & Analysis - MarketBeat
Raymond James Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
Piper Sandler reiterates Climb Bio stock rating on IgAN opportunity By Investing.com - Investing.com Nigeria
Climb Bio, Inc. participates in HC Wainwright fireside chat to outline strategic direction - Traders Union
CLYM: Multiple clinical data readouts in 2024 will shape pivotal study plans and market positioning - TradingView
Piper Sandler reiterates Climb Bio stock rating on IgAN opportunity - Investing.com
Piper Sandler Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Climb Bio (CLYM) price target increased by 18.34% to 19.62 - MSN
Climb Bio (CLYM) Q1 2026 Earnings: Why the Beat MattersFree Market Insights - Newser
Number of shareholders of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress - The Manila Times
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 ... - Caledonian Record
New immune thrombocytopenia antibody data headed to EHA 2026 - Stock Titan
H.C. Wainwright raises Climb Bio stock price target on trial progress - Investing.com Nigeria
Climb Bio to Present at Upcoming Investor Conferences - markets.businessinsider.com
H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $20 - Moomoo
H.C. Wainwright raises Climb Bio stock price target on trial progress By Investing.com - Investing.com South Africa
Biotech Climb Bio plans May and June investor talks online - Stock Titan
TradingKey - TradingKey
Climb Bio (CLYM) price target increased by 34.43% to 15.67 - MSN
Climb Bio (NASDAQ:CLYM) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Budo judo moves aplenty for Climb in autoimmune - BioWorld News
Baird Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $21 - Moomoo
Climb Bio, Inc. 1Q 2026: Net income $(13.7M), EPS $(0.20) — 10-Q Summary - TradingView
Climb Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Climb Bio (NASDAQ: CLYM) trims Q1 2026 loss and raises $110M to fund pipeline - Stock Titan
[8-K] Climb Bio, Inc. Reports Material Event - Stock Titan
$110M financing gives Climb Bio room for multiple 2026 drug data readouts - Stock Titan
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates - marketscreener.com
A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $19 to $22 - Moomoo
Wedbush Adjusts Price Target on Climb Bio to $15 From $14, Maintains Outperform Rating - Moomoo
Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE - Yahoo Finance
Climb Bio Secures 110 Million Dollars Through Private Stock Placement - HarianBasis.co
Climb Bio reports B-cell depletion data for budoprutug trial By Investing.com - Investing.com South Africa
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing - Insider Monkey
Finanzdaten der Climb Bio Inc-Aktie (CLYM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Climb Bio Inc-Aktie (CLYM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thomas Stephen Basil | Director |
Feb 26 '26 |
Sale |
7.01 |
16,313 |
114,289 |
154,657 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):